Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients.

Szczegóły
Abstrakt

Tytuł:: Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients.
Autorzy:: Rivero-Juarez A; Infectious Diseases Unit, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba, Spain.
Gonzalez R
Camacho A
Manzanares-Martin B
Caruz A
Martinez-Peinado A
Torre-Cisneros J
Pineda JA
Peña J
Rivero A
Źródło:: PloS one [PLoS One] 2013 Apr 16; Vol. 8 (4), pp. e61992. Date of Electronic Publication: 2013 Apr 16 (Print Publication: 2013).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:: HIV Infections/*metabolism
Hepacivirus/*pathogenicity
Receptors, KIR3DS1/*genetics
Adult ; Coinfection ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Reverse Transcriptase Polymerase Chain Reaction ; Viral Load
References:: HIV Med. 2011 Sep;12(8):487-93. (PMID: 21375685)
Nat Genet. 2002 Aug;31(4):429-34. (PMID: 12134147)
Genes Immun. 2005 Dec;6(8):683-90. (PMID: 16121209)
Science. 2011 Jan 7;331(6013):44-9. (PMID: 21212348)
Annu Rev Immunol. 1999;17:189-220. (PMID: 10358757)
Hepatology. 2012 Sep;56(3):841-9. (PMID: 22431186)
J Immunol. 2007 Jan 15;178(2):647-51. (PMID: 17202323)
Gastroenterology. 2011 Oct;141(4):1231-9, 1239.e1-2. (PMID: 21741920)
Annu Rev Immunol. 2005;23:225-74. (PMID: 15771571)
Antiviral Res. 2010 Jan;85(1):303-15. (PMID: 19887087)
Hepatology. 2009 Apr;49(4):1335-74. (PMID: 19330875)
J Exp Med. 2007 Nov 26;204(12):3027-36. (PMID: 18025129)
Mol Immunol. 2002 Feb;38(9):637-60. (PMID: 11858820)
J Antimicrob Chemother. 2012 Jan;67(1):202-5. (PMID: 21990051)
Hepatology. 2012 Aug;56(2):444-54. (PMID: 22331604)
Nat Genet. 2007 Jun;39(6):733-40. (PMID: 17496894)
Science. 2004 Aug 6;305(5685):872-4. (PMID: 15297676)
Blood. 2008 Jul 15;112(2):435-43. (PMID: 18385451)
Nature. 2009 Sep 17;461(7262):399-401. (PMID: 19684573)
Tissue Antigens. 2002 Mar;59(3):184-93. (PMID: 12074708)
Curr Opin HIV AIDS. 2011 Nov;6(6):514-26. (PMID: 22001895)
AIDS Res Hum Retroviruses. 2007 Mar;23(3):451-5. (PMID: 17411378)
PLoS Med. 2011 Sep;8(9):e1001092. (PMID: 21931540)
AIDS. 2012 May 15;26(8):1009-15. (PMID: 22382144)
J Infect Dis. 2005 Jul 1;192(1):162-5. (PMID: 15942906)
PLoS Pathog. 2007 Apr;3(4):e43. (PMID: 17447840)
Nat Rev Gastroenterol Hepatol. 2011 May;8(5):257-64. (PMID: 21468124)
Clin Infect Dis. 2010 Oct 1;51(7):788-95. (PMID: 20804372)
Gastroenterology. 2010 Jul;139(1):120-9.e18. (PMID: 20399780)
AIDS. 2011 Jul 17;25(11):1415-20. (PMID: 21572301)
Hepatology. 2010 Dec;52(6):1888-96. (PMID: 20931559)
Hepatology. 2012 Jan;55(1):39-48. (PMID: 21898483)
Hepatology. 2011 Nov;54(5):1559-69. (PMID: 21983945)
Nature. 2011 Aug 03;476(7358):96-100. (PMID: 21814282)
J Virol. 2010 Jan;84(1):475-81. (PMID: 19846535)
Hepatology. 2010 Apr;51(4):1168-75. (PMID: 20077564)
Substance Nomenclature:: 0 (Receptors, KIR3DS1)
Entry Date(s):: Date Created: 20130425 Date Completed: 20131114 Latest Revision: 20211021
Update Code:: 20240104
PubMed Central ID:: PMC3629002
DOI:: 10.1371/journal.pone.0061992
PMID:: 23613999
: Czasopismo naukowe

Pełny tekst

Aim: To evaluate the influence of the presence of the killer cell immunoglobulin-like receptor (KIR) 3DS1 on HCV treatment response in HIV/HCV genotype 1 co-infected patients.
Methods: HIV/HCV co-infected patients were included. KIR3DS1, their specific HLA-B ligands and IL28B gene were genotyped. Reductions of plasma HCV RNA levels between baseline and week 1, week 2 and week 4 were analyzed for IL28B genotype and KIR3DS1 (HLA Bw4 or Bw6). Rapid and sustained virological response (RVR and SVR) rates were also analyzed.
Results: Sixty HIV/HCV genotype 1 co-infected patients were included. Patients with KIR3DS1 and Bw4 had higher rates of HCV viral decline than those who were not carriers of KIR3DS1 (week 1: p = 0.01; week 2: p = 0.038; week 4: p = 0.03). Patients carrying KIR3DS1/Bw4 had higher rates of RVR and SVR than those who did not carry KIR3DS1 (RVR: 46.15% versus 17.02%, p = 0.012; SVR: 63.6% versus 13 26.5%, p = 0.031). With respect to patients carrying the IL28B-CC genotype, those with KIR3DS1/Bw4 had greater rates of HCV viral clearance (week 1: p<0.001; week 2: p = 0.01; week 4: p = 0.02), RVR (p = 0.015) and SVR (p = 0.029) than those not carrying KIR3DS1.
Conclusion: Our results show that the KIR3DS1 genotype has a positive effect on HCV viral clearance during the first weeks of Peg-IFN/RBV treatment in HCV/HCV co-infected patients bearing genotype 1, and higher RVR and SVR rates.

Informacja